Results of treatment of 33 patients with peritoneal mesothelioma

Sebbag, Gilbert; Yan, Hui; Shmookler, Barry M.; Chang, David; Sugarbaker, Paul H.

doi:10.1046/j.1365-2168.2000.01571.x

Cited by 148 publications

(85 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior reports have identified localized mesothelioma (Kitagawa et al, 1996) and well-differentiated papillary mesothelioma (Goldblum and Hart, 1995) as mesothelioma subtypes associated with favorable prognosis. Once analysis is confined to diffuse malignant mesothelioma, epithelial subtype is associated with prolonged survival compared with biphasic and sarcomatous subtypes (Sebbag et al, 2000;Sugarbaker et al, 2003). It is unclear whether this clinical difference is attributable to aggressive growth patterns, frequent chemoresistance of mixed/sarcomatous tumors or to other biological factors.…”

Section: Introductionmentioning

confidence: 99%

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

et al. 2006

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

et al. 2006

View full text Add to dashboard Cite

“…51,52 As in pleural MM, the biphasic and sarcomatoid subgroups have a significantly poorer prognosis and are less amenable to treatment overall. 53,54 While definitions of pleural MM have proposed a minimum of 10% spindled growth for a biphasic designation, the less common occurrence of biphasic histologic appearance and the distinctly poorer prognosis of this group in PMM may make a minimum value less practical. It remains unclear whether identification of any component of malignant spindled histology portends a poor prognosis in PMM.…”

Section: Morphologic Features Relatedmentioning

confidence: 99%

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group

Husain

Colby

Ordóñez

et al. 2013

Archives of Pathology & Laboratory Medicine

479

559

View full text Add to dashboard Cite

“…1 Pleural malignant mesotheliomas are 10-30-fold more common than their peritoneal counterparts. 2,3 Regardless of site of origin, the prognosis is usually poor with a median survival of 4-12 months for pleural tumors 4 and less than 1 year for peritoneal tumors. 3 Systemic chemotherapy and radiation does little to improve the outcome.…”

mentioning

confidence: 99%

Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers

et al. 2004

View full text Add to dashboard Cite

Diffuse malignant mesothelioma of the peritoneum is a rare diagnosis. Despite many histopathologic similarities between peritoneal and pleural tumors, clinical and prognostic features may be quite different. There is a paucity of data evaluating molecular features of peritoneal mesotheliomas. Therefore, we compared the results of a battery of immunohistochemical markers, some with therapeutic implications, in patients with primary peritoneal or pleural mesotheliomas. We examined 24 peritoneal and nine pleural malignant mesotheliomas with a battery of immunohistochemical markers (cytokeratin AE1/3, calretinin, c-kit/CD117, desmin, epidermal growth factor receptor (EGFR), estrogen receptors (ER), progesterone receptors (PR), MIB-1, and cleaved caspase-3) in an attempt to distinguish any differences in this tumor arising in these two distinct locations. The results indicate that the only marker to show a significant difference in its staining pattern between these two sites was EGFR (P ¼ 0.0004). In all, 92% (22/24) of peritoneal tumors demonstrated 3 þ or 4 þ immunoreactivity with EGFR, opposed to only 33% (3/9) pleural tumors. There was no significant difference in immunoreactivity between the pleural and peritoneal tumors with c-kit, ER, PR, cleaved caspase 3, calretinin, and desmin. There was a trend toward increased cytokeratin (P ¼ 0.07) and MIB-1 (P ¼ 0.08) expression in the peritoneal group. There was no significant difference in age, sex, or histologic subtype between the two locations. In conclusion, despite similarities between peritoneal and pleural mesothelioma, there are differences between this neoplasm arising in these two sites. The EGFR expression is more pronounced in peritoneal tumors compared to pleural tumors. The increased expression of EGFR in the peritoneal lesions may be of clinical significance with the recent emergence of epidermal growth factor receptor-targeted therapies.

show abstract

Results of treatment of 33 patients with peritoneal mesothelioma

Abstract: Although peritoneal mesothelioma is rare, progress in its management has occurred. Survival has been extended and selection factors by which patients may be allocated to aggressive management strategies have been defined.

Cited by 148 publications

References 24 publications

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group

Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers

Contact Info

Product

Resources

About